ArticleDigestive diseases and sciences2026
SERPINE1-Driven MAPK Activation Enhances Cuproptosis Resistance and Angiogenic Potential in Colorectal Cancer.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conserved Epithelial Remodeling Programs Underlie Pediatric Juvenile Colorectal Polyps Associated with Allergic Sensitization.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a significant health challenge with high incidence and mortality rates. While SERPINE1 is overexpressed in CRC and linked to poor patient outcomes, the detailed mechanisms by which it promotes tumor progression remain poorly understood.
methodsSERPINE1 was identified as a cuproptosis-related angiogenic protein using the GEO database. Expression and prognostic impact of SERPINE1 in CRC were analyzed with the TCGA database. To forecast the pathways SERPINE1 might enrich, we deployed gene set enrichment analysis. SERPINE1 mRNA levels were quantified via qPCR. Co-immunoprecipitation (Co-IP) assay was performed to analyze the interaction between SERPINE1 and uPA/uPAR. Western blot (WB) was conducted to gauge protein expression of MAPK signaling components, cuproptosis markers, and SERPINE1 itself. Changes in cell viability were assessed using CCK-8. Angiogenesis assays probed how SERPINE1 may impact the angiogenic ca of CRC cells. Xenograft tumor models were established in adult nude mice to track tumor growth and volume changes.
resultsSERPINE1 was highly expressed in CRC, with substantial enrichment in the MAPK signaling pathway, and this overexpression is associated with unfavorable prognoses. CRC cells overexpressing SERPINE1 showed increased cell viability and angiogenic capacity, while expression of cuproptosis-related genes was markedly reduced. Mechanistically, SERPINE1 activates p38/MAPK pathway, thereby enhancing angiogenesis and cuproptosis resistance in CRC. This process may be associated with the interaction between SERPINE1 and uPA/uPAR.
conclusionOur study illuminates how SERPINE1, often overexpressed in CRC, leverages the p38/MAPK pathway to bolster cuproptosis resistance and angiogenesis, offering a promising avenue for anti-angiogenic strategies in CRC treatment.
Indexed as
Identifiers
41661494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.